Opinion|Videos|February 3, 2025
BRCA Testing in Early-Stage and Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD, Casey Degen, MD
Panelists discuss their approach to BRCA testing in early-stage versus metastatic breast cancer patients, highlighting the 2024 American Society of Clinical Oncology (ASCO) guidelines for germline testing and exploring which patients are not tested for BRCA, as well as how they differentiate between germline and somatic testing approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. Shatsky asks Dr. Degen: Please discuss how you approach BRCA testing in early stage versus metastatic breast cancer patients. Please also briefly highlight the ASCO guidelines that were recently updated in 2024 for germline testing in patients with breast cancer (
https://ascopubs.org/doi/full/10.1200/JCO.23.02225 ).- What patients are you not testing for BRCA?
- How do you differentiate your approach for germline versus somatic testing?
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Advertisement
Advertisement
Trending on OncLive
1
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5